Publications by authors named "Vicki Goodman"

Claim this Profile
C
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Michelle Casey, Georgina V Long, Vicki Goodman

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Vicki Goodman

Thyroid· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
Daniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, Anne O'Hagan, Patricia Haney, Vicki L Goodman

J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Paolo A Ascierto, David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan, Vicki L Goodman

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Stephen R D Johnston, Henry Gómez, Salomon M Stemmer, Maria Richie, Michael Durante, Vicki Goodman

Breast Cancer Res Treat· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Georgina V Long, Uwe Trefzer, Michael A Davies, Richard F Kefford, Paolo A Ascierto, Vicki Goodman

Lancet Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Vicki Goodman

Lancet· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
David S Hong, Luis Vence, Gerald Falchook, Laszlo G Radvanyi, Chengwen Liu, Vicki Goodman

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.
Chun-Fang Xu, Brian H Reck, Vicki L Goodman, Zhengyu Xue, Lingkang Huang

J Hepatol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Michael Brave, Vicki Goodman, Edvardas Kaminskas, Ann Farrell, William Timmer

Clin Cancer Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Vicki L Goodman, Edwin P Rock, Ramzi Dagher, Roshni P Ramchandani, Sophia Abraham

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Edwin P Rock, Vicki Goodman, Janet X Jiang, Kooros Mahjoob, S Leigh Verbois

Oncologist· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control of copper status for cancer therapy.
Vicki L Goodman, George J Brewer, Sofia D Merajver

Curr Cancer Drug Targets· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis